Compare Charles River Laboratories Intl. Inc (CRL) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Expeditors International of Wshngtn Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231.21 (market cap $11.14B), while Expeditors International of Wshngtn Inc trades at $178.61 (market cap $23.31B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 2.1× Charles River Laboratories Intl. Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | EXPD | |
|---|---|---|
Market Cap | $11.14B | $23.31B |
Sector | Health | Industrials |
52-Week High | $233.60 | $178.22 |
52-Week Low | $145.57 | $111.37 |
Enterprise Value | $14.00B | $22.56B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EXPD trades at $175.50, up 2.02% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, revenue growth to $11.07B in 2025, and impressive ROE of 36.59%. Recent dividend payments and positive analyst coverage highlight financial stability, though valuation metrics appear elevated with P/E of 28.35.
Outlook remains positive with earnings momentum and e-commerce tailwinds, but risks include stretched valuation, mixed analyst sentiment (only 12% buy ratings), and economic sensitivity. The stock trades above consensus price target of $159, suggesting limited near-term upside potential despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
